537 results about "Central nerve system" patented technology

The invention provides a ziconotide nasal-brain delivery preparation which is high in brain targeting, safe and noninvasive and directly enters the brain through nasal administration. The nasal-brain delivery preparation comprises an active component ziconotide and an absorption enhancer, wherein the absorption enhancer is selected from one or more of dodecyl-beta-D-maltoside (DDM), menthol, hydroxypropyl-beta-cyclodextrin (HP-beta-CD), sodium glycocholate (SGC) and related derivatives thereof. The absorption enhancer with a specific type and content and the ziconotide cooperate and act together, so that the ziconotide bypasses a blood brain barrier, enters the brain through a nasal olfactory mucous membrane, forms a medicine storage bank in an olfactory bulb, is slowly released to the brain and keeps a long-term medicine effect, and therefore, a traditional ziconotide intrathecal administration mode is abandoned; the ziconotide nasal-brain administration mode is created, and the ziconotide nasal-brain administration method is a new-generation therapy for pain diseases related to the central nervous system.

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention discloses a brain-targeted active oxygen responsive hydrogen sulfide donor liposome, a preparation method and an application, and belongs to the technical field of pharmaceutical preparations, the structure of the brain-targeted active oxygen responsive hydrogen sulfide donor liposome comprises a lipid material and a hydrogen sulfide donor encapsulated in the lipid material, the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid, and the lipid material comprises phospholipid, cholesterol, active oxygen sensitive lipid and brain-targeted lipid. The active oxygen sensitive lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and an active oxygen sensitive bond, and the brain-targeted lipid comprises a phospholipid lipophilic part, a polyethylene glycol hydrophilic part and brain-targeted peptide. The hydrogen sulfide donor lipidosome can penetrate through a blood brain barrier, target neuronal cells, respond to an active oxygen environment of a focus part and sensitively release a hydrogen sulfide donor, so that hydrogen sulfide is distributed in the focus neuronal cells, active oxygen and active nitrogen substances are effectively removed, oxidation and nitration stress are inhibited, and damage and death of the neuronal cells are reduced; the growth and functional recovery of neuronal cells are promoted, and the application prospect in the aspect of treating central nervous system injury diseases is good.

The invention relates to the technical field of biological medicines, in particular to a recombinant rabies virus nano-antibody fused with a solubilizing oligopeptide and a cell penetrating peptide and application of the recombinant rabies virus nano-antibody in preparation of rabies prevention and treatment products. The recombinant rabies virus nano-antibody fused with the solubilizing oligopeptide and the cell penetrating peptide comprises a humanized rabies virus nano-antibody, and the C end of the humanized rabies virus nano-antibody is fused with a solubilizing tag peptide P17 and the cell penetrating peptide. The recombinant rabies virus nano antibody utilizes a prokaryotic expression system, is low in cost, has excellent cell membrane and BBB penetrating ability, can enter a central nervous system from veins for virus neutralization treatment, and has an efficient passive immune effect.

The present letter invention provides an engineered AAV capsid in which at least one protein on the capsid is modified to include an n-mer motif that promotes transduction of the capsid into the central nervous system (CNS) by interaction with a transferrin receptor. Further embodiments provide a carrier system comprising one or more carriers encoding an AAV capsid and a method of delivering a cargo to a CNS. The methods comprise administering an AAV capsid according to embodiments described herein in vivo or in vitro, and the AVV capsid comprises one or more carrier molecules.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof in the central nervous system or ex vivo. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a disease (e.g., a neurological disease), preventing a disease (e.g., neurological disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof.

The present invention relates to antibodies or antibody fragments that bind to human and non-human primate transferrin receptors. The antibodies described herein can be used as agents to deliver pharmaceutical compounds into or through cells during receptor-mediated endocytosis and / or transendocytosis processes. As transferrin receptors are also present in the blood brain barrier endothelial cells, one aspect of the invention provides means and methods to increase delivery of pharmaceutical compounds to the central nervous system.

Described herein are shock wave catheters and methods of use thereof for delivering an active agent of a drug to the CNS via a body lumen or cavity, such as sinonasal cavity, which can bypass the blood-brain barrier (BBB). The catheters described herein can be advanced through an intranasal passage to the nasal cavity such that at least a portion of the enclosure is disposed in the nasal cavity. The enclosure can be coated with a drug coating. The method can include filling the enclosure with a conductive fluid. At least one shock wave can be generated at a shock wave emitter of the catheter disposed within the enclosure. The at least one shock wave can cause a therapeutically effective amount of the active agent of the drug coating to be delivered to the CNS via tissue of the nasal cavity, in turn, treating central nervous system diseases.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

A method for predicting a development level difference of language and communication capability normality of a healthy infant or toddler. The method comprises obtaining electroencephalogram (EEG) or magnetoencephalogram (MEG) waveform data of a healthy infant or toddler caused by external auditory stimulus; obtaining, from the EEG or MEG waveform data, quantitative data that represents measurement index data of a central nervous system caused by the external auditory stimulus; and using a data set to train a machine learning classifier, so as to obtain a prediction result. Further provided are a relevant tool and an integrated system.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition and use thereof. The compounds provided by the present disclosure are useful for the effective treatment of PDE4-related diseases and disorders, including but not limited to respiratory tract inflammatory diseases, inflammatory bowel diseases, arthritis diseases, skin inflammatory diseases, eye inflammatory diseases, and diseases or cancers of the peripheral or central nervous system. # imgabs0 #

The present disclosure provides a method of producing a non-human mammalian animal model comprising human neural tissue, the method comprising introducing a first human neural organoid into a central nervous system location of a newborn non-human mammal; and allowing the newborn non-human mammal to mature to produce the non-human mammalian animal model comprising human neural tissue. The present disclosure provides a method of modeling a neuropsychiatric disorder. The present disclosure also provides a method of determining the effectiveness of a candidate agent on a neuropsychiatric disorder. The present disclosure provides a method for altering the behavior of a mammal. Also provided are non-human mammalian animal models comprising human neural tissue.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention discloses a tea leaf theanine composition for protecting a central nervous system as well as a preparation method and application thereof, relates to the field of common foods and health-care foods, and aims to solve the problems that most of existing central nervous protection products are single components or are simply compounded, the synergistic effect is weak and the bioavailability is low. The preparation method comprises the following steps: S1, mixing the tea leaf theanine, the emblic leafflower fruit powder, the ginkgo leaf extract, the wolfberry fruit powder and other raw materials according to a specific ratio, and performing high-temperature sterilization and cooling to obtain a fermentation substrate; s2, inoculating a composite activation microbial inoculum composed of plant lactobacillus, lactobacillus acidophilus and lactobacillus reuteri, and carrying out constant-temperature anaerobic fermentation; and S3, freezing and centrifuging at 4 DEG C, concentrating with an RO membrane, and freezing and drying to obtain the composition. The viable count of the complex microbial inoculant reaches 2.0 * 10 < 9 >-3.0 * 10 < 9 > CFU / mL, and the strain ratio and the fermentation process are optimized. The composition has a synergistic effect of multiple components, can efficiently protect nervous centralis, and is suitable for preparing related common food, health food or functional food.

The invention discloses an Alzheimer's disease transnasal microneedle drug delivery system and a preparation method thereof, and relates to the technical field of biological medicine, the microneedle drug delivery system comprises a microneedle substrate and a microneedle tip; the microneedle tip comprises a medicine carrying exosome, hyaluronic acid and polyvinylpyrrolidone; the drug-loaded exosome comprises a tobacco leaf exosome, the surface of the tobacco leaf exosome is connected with brain-targeted peptide RVG29, and donepezil is wrapped in the tobacco leaf exosome. The invention further discloses a preparation method of the microneedle drug delivery system. According to the nasal microneedle drug delivery system for Alzheimer's disease, the delivery efficiency of a small molecule drug donepezil to the brain is enhanced, and the nasal microneedle drug delivery system has the advantages of being high in safety, good in curative effect and good in targeting property; the problems that in the prior art, small molecule medicine donepezil difficultly passes through the blood brain barrier and enters the central nervous system, the medicine delivery efficiency is low, the treatment effect is low, and side effects are many are solved.

The invention discloses tNGS primers, a kit and a method for simultaneously detecting multiple central nervous system pathogens. The primer comprises primers as shown in SEQ NO.: 1 to SEQ NO.: 492 in a sequence table. The primer can be used for simultaneously screening multiple central nervous system pathogens, and has good sensitivity, stability and repeatability.

The invention discloses a nutritional composition for promoting central nervous system development and application. The invention provides a nutritional composition for promoting the development of a central nervous system. The nutritional composition comprises the following necessary components: a breast milk oligosaccharide component and a casein phosphopeptide component, moreover, in the composition, the mass ratio of the breast milk oligosaccharide component to the casein phosphopeptide component is (1-100): (500-1). According to the invention, the breast milk oligosaccharide component and the casein phosphopeptides are matched to prepare the nutritional composition, and the nutritional composition can significantly promote nerve development such as neuronal maturation, synaptic generation and myelin sheath formation.

The present disclosure relates to a neurostimulation system, in particular for Cortical and / or Deep Brain Stimulation and / or Central Nervous System (CNS) neurostimulation / neuromodulation and / or Peripheral Nervous System (PNS) neurostimulation / neuromodulation and / or Vagus Nerve Stimulation, comprising:at least one implant unit comprising:at least one first antenna, andat least one lead having at least one electrode array with at least one electrode; andat least one wearable device comprising at least one second antenna,wherein the at least one wearable device is configured to wirelessly control and wirelessly communicate with the at least one implant unit, and wherein the at least one electrode is made of reduced graphene oxide, such as hydrothermally reduced graphene oxide.

The invention relates to an artificial visual nervous system based on a bimodal neural device, which comprises a bimodal visual information calculation array composed of a physical convolution kernel array and a synaptic calculation array, and is characterized in that the physical convolution kernel array is used for receiving an ambient light signal and converting the ambient light signal into an electric signal for output; the synaptic calculation array is used for receiving the electric signals and converting the electric signals into visual signals, and the physical convolution kernel array and the synaptic calculation array are each composed of a plurality of bimodal transistors. The method has excellent bimodal cooperative computing capability, and realizes image feature extraction and preprocessing by simulating a receptive field mechanism (excitement / inhibitory response) of the retina bipolar cells through the physical convolution kernel array; the synaptic plasticity (LTP / LTD mechanism) of a central nervous system is simulated in combination with a synaptic calculation array, advanced calculation of visual signals is completed, and a complete optic nerve bionic system is formed by means of the array composed of single devices.

The present invention provides CXCR4 inhibitors of formula (I) and pharmaceutically acceptable salts thereof, as well as methods of using them in the treatment of neurological and CNS diseases, disorders, and conditions. The provided compounds are inhibitors of CXCR4 and are therefore useful for treating one or more disorders associated with CXCR4 activity. Thus, in certain embodiments, the present invention provides a method for treating a CXCR4-mediated disorder, comprising administering to a patient in need thereof a CXCR4 inhibitor described herein, such as a compound of formula I or a pharmaceutically acceptable salt thereof. Certain embodiments of the present invention are directed to the use of CXCR4 inhibitors that, when administered to a subject, cross the blood-brain barrier (BBB) ​​and enter the brain and central nervous system (CNS). JPEG2026502774000083.jpg3135

The invention relates to the technical field of natural medicines, and discloses huperzine A C12 site arylation series derivatives and a preparation method thereof, and application of the derivatives in preparation of medicines for treating central nervous system degenerative diseases. The derivative has a structure as shown in a general formula I. According to the preparation method, a natural product huperzine A is taken as a raw material, aryl bromide is taken as a substrate, one-step synthesis is carried out through palladium-catalyzed heck coupling reaction, and the compound has the advantages of high chemical selectivity, no need of functional group protection, rapidness and the like. In-vitro enzyme activity and cell experiments prove that the derivative not only shows potential acetylcholin esterase inhibitory activity, but also has high efficiency, low toxicity and better neuroprotective activity, and has a prospect in clinical treatment of Alzheimer's disease. The preparation of the derivatives also provides a design thought for the development of novel central nervous system disease treatment drugs.

The invention relates to the technical field of medicines, in particular to application of a mesenchymal stem cell exosome in preparation of a thermoplegia neuroprotective agent. It is found through experiments that MSC-Exos can remarkably promote polarization conversion of microglial cells from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, and therefore damage, caused by heat stroke, to a central nervous system is relieved.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.

Systems and methods for radiofrequency neurotomy. Systems include needles with deployable filaments capable of producing lesions at target volumes, which may include a target nerve. Ablation of at least a portion of the target nerve may inhibit the ability of the nerve to transmit signals, such as pain signals, to the central nervous system. The lesion may facilitate procedures by directing energy towards the target nerve and away from collateral structures. Example anatomical structures include lumbar, thoracic, and cervical medial branch nerves and rami and the sacroiliac joint.

A conjugate comprising a ligand that targets a folate receptor linked to an acrolein scavenger drug; a composition comprising same; a method of using the conjugate or the composition to scavenge acrolein, alone or in further combination with other reactive aldehyde species, in a subject with neurotrauma; and a method of delivering an acrolein scavenger or an imaging agent to the central nervous system (CNS) of a patient with inflammation in the CNS.

A promoter on an AAV vector was changed to an Iba1 promoter, and a configuration that combined a miR-9 complementary sequence (miR-9T) and a miR-129 complementary sequence (miR-129T) was adopted. An exogenous gene was clarified to be efficiently and specifically expressed in microglia by using this vector, resulting in that an AAV vector that could efficiently and specifically express an exogenous gene in microglia of the central nervous system, was found.

The present invention discloses novel molecules consisting of N-methyl-D-aspartate receptor (NMDAR) antagonists-polymer conjugates having a general structure D-(X-Poly-T)n, wherein D is an high affinity, i.e., (+)-, (−)-, or (±)-dizocilpine, or a low affinity, i.e., (+)-, (−)-, or (±)-methadone, CNS active NMDAR antagonist, n is an integer comprised between 1 and 6. X is a stable (enzymatically and / or hydrolytically under physiological conditions) linker comprising a covalent bond or a chain of atoms that covalently attaches a small molecule NMDAR antagonist drug moiety to the Poly derivative. Poly is a covalently bonded chain of repeating monomer units that form a polymer or an oligomer backbone of synthetic or natural origin. T, if present, is either another molecule of D, or a terminal group of Poly, represented by any suitable chemical group which, depending upon preference, is unreactive or reactive with other chemical moieties, or has a targeting property.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.